Results of the multicenter evaluation of a novel homogeneous immunoassay for digoxin based on the cloned enzyme donor immunoassay technology.
A new CEDIA assay for the measurement of digoxin in serum on random access analyzers was evaluated by twelve laboratories in Europe and the United States. Studies on the analytical range, reproducibility, calibration stability, recovery in controls, interlaboratory comparability, comparability with routine methods, and the effect of various interfering factors have been performed and the results are presented in this paper. The analytical performance was comparable to that of routine methods provided the manual pipetting step for pre-incubation was performed with accurate pipettes. A major advantage of the CEDIA Digoxin assay in terms of convenience is the simple two-point calibration procedure. Moreover, digoxin can be determined within 15 minutes after receiving the samples on random access analyzers like Boehringer Mannheim/Hitachi analysis systems. Thus, the CEDIA Digoxin assay represents an attractive alternative to the measurement of digoxin on dedicated immunochemical assay systems.
Jarausch
J
J
Boehringer Mannheim GmbH, Federal Republic of Germany.
Collinsworth
W
W
Cano
Y
Y
Hafner
G
G
Hammer
E
E
Malandain
H
H
Pokieser
L
L
Redondo
F L
FL
Schlebusch
H
H
Taylor
A
A
D002138:Calibration; D004077:Digoxin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring / Q000295:instrumentation*; D006801:Humans; D007124:Immunoenzyme Techniques / Q000295:instrumentation*; D011786:Quality Control; D012016:Reference Values
D004077:Digoxin